123 related articles for article (PubMed ID: 15518911)
1. The development of VIP-ellipticine conjugates.
Moody TW; Czerwinski G; Tarasova NI; Moody DL; Michejda CJ
Regul Pept; 2004 Dec; 123(1-3):187-92. PubMed ID: 15518911
[TBL] [Abstract][Full Text] [Related]
2. VIP-ellipticine derivatives inhibit the growth of breast cancer cells.
Moody TW; Czerwinski G; Tarasova NI; Michejda CJ
Life Sci; 2002 Jul; 71(9):1005-14. PubMed ID: 12088760
[TBL] [Abstract][Full Text] [Related]
3. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
[TBL] [Abstract][Full Text] [Related]
4. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors.
Virgolini I; Yang Q; Li S; Angelberger P; Neuhold N; Niederle B; Scheithauer W; Valent P
Cancer Res; 1994 Feb; 54(3):690-700. PubMed ID: 7905785
[TBL] [Abstract][Full Text] [Related]
5. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
[TBL] [Abstract][Full Text] [Related]
6. VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors.
Cunha-Reis D; Ribeiro JA; Sebastião AM
Brain Res; 2005 Jul; 1049(1):52-60. PubMed ID: 15935995
[TBL] [Abstract][Full Text] [Related]
7. Generation of PEGylated VPAC1-selective antagonists that inhibit proliferation of a lung cancer cell line.
Pan CQ; Hamren S; Roczniak S; Tom I; DeRome M
Peptides; 2008 Mar; 29(3):479-86. PubMed ID: 17942192
[TBL] [Abstract][Full Text] [Related]
8. Coronary vascular effects of vasoactive intestinal peptide in the isolated perfused rat heart.
Sawmiller DR; Henning RJ; Cuevas J; Dehaven WI; Vesely DL
Neuropeptides; 2004 Oct; 38(5):289-97. PubMed ID: 15464194
[TBL] [Abstract][Full Text] [Related]
9. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.
Vaccari S; Latini S; Barberi M; Teti A; Stefanini M; Canipari R
J Endocrinol; 2006 Oct; 191(1):287-99. PubMed ID: 17065411
[TBL] [Abstract][Full Text] [Related]
10. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
[TBL] [Abstract][Full Text] [Related]
11. Retinoic acid down-regulates VPAC(1) receptors and TGF-beta 3 but up-regulates TGF-beta 2 in lung cancer cells.
Jakowlew SB; Zakowicz H; Moody TW
Peptides; 2000 Dec; 21(12):1831-7. PubMed ID: 11150643
[TBL] [Abstract][Full Text] [Related]
12. Ac His1 [D-Phe2, K15, R16, L27] VIP (3-7)/GRF (8-27)--a VPAC1 receptor antagonist--is an inverse agonist on two constitutively active truncated VPAC1 receptors.
Vertongen P; Langlet C; Langer I; Gaspard N; Robberecht P
Peptides; 2004 Nov; 25(11):1943-9. PubMed ID: 15501526
[TBL] [Abstract][Full Text] [Related]
13. A complete substitutional analysis of VIP for better tumor imaging properties.
Bhargava S; Licha K; Knaute T; Ebert B; Becker A; Grötzinger C; Hessenius C; Wiedenmann B; Schneider-Mergener J; Volkmer-Engert R
J Mol Recognit; 2002; 15(3):145-53. PubMed ID: 12203840
[TBL] [Abstract][Full Text] [Related]
14. Long-acting analogue of vasoactive intestinal peptide, [R15, 20, 21, L17]-VIP-GRR (IK312532), protects rat alveolar L2 cells from the cytotoxicity of cigarette smoke.
Onoue S; Endo K; Ohmori Y; Yamada S; Kimura R; Yajima T; Kashimoto K
Regul Pept; 2004 Dec; 123(1-3):193-9. PubMed ID: 15518912
[TBL] [Abstract][Full Text] [Related]
15. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
16. Hexanoylation of a VPAC2 receptor-preferring ligand markedly increased its selectivity and potency.
Langer I; Gregoire F; Nachtergael I; De Neef P; Vertongen P; Robberecht P
Peptides; 2004 Feb; 25(2):275-8. PubMed ID: 15063009
[TBL] [Abstract][Full Text] [Related]
17. Spatial approximation between the C-terminus of VIP and the N-terminal ectodomain of the VPAC1 receptor.
Ceraudo E; Tan YV; Couvineau A; Lacapere JJ; Laburthe M
Ann N Y Acad Sci; 2006 Jul; 1070():180-4. PubMed ID: 16888162
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of ellipticine-estradiol conjugates.
Devraj R; Barrett JF; Fernandez JA; Katzenellenbogen JA; Cushman M
J Med Chem; 1996 Aug; 39(17):3367-74. PubMed ID: 8765520
[TBL] [Abstract][Full Text] [Related]
19. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
Sotomayor S; Carmena MJ; Schally AV; Varga JL; Sánchez-Chapado M; Prieto JC; Bajo AM
Int J Oncol; 2007 Nov; 31(5):1223-30. PubMed ID: 17912451
[TBL] [Abstract][Full Text] [Related]
20. VIP differentially activates beta2 integrins, CR1, and matrix metalloproteinase-9 in human monocytes through cAMP/PKA, EPAC, and PI-3K signaling pathways via VIP receptor type 1 and FPRL1.
El Zein N; Badran B; Sariban E
J Leukoc Biol; 2008 Apr; 83(4):972-81. PubMed ID: 18174366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
